Structural Heart Devices Market

Structural Heart Devices Market (Product: Biological/Tissue Valves, Mechanical Heart Valves, Annuloplasty Rings, Occluders, and Accessories; Procedure: Replacement Procedures and Repair Procedures; Indication: Valve Stenosis, Valve Regurgitation, Cardiomyopathy, Congenital Heart Defects, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Polymer-based Cardio Vascular Replacement to Boost Structural Heart Devices Market

Structural heart devices technology has seen a paradigm shift with the advent of non-invasive procedures to treat aortic stenosis and mitral regurgitation. From a previously sluggish approach, there seems to be a spate of activity characterized by investor excitement and massive research & development (R&D) initiatives regarding minimally-invasive heart valve technologies. For cardio-thoracic surgeons and interventional cardiologists, this arena offers tremendous scope and potential vis-à-vis traditional open heart surgery that is associated with severe side-effects.

Industry leaders and clinicians are viewing this as the answer to the growing unmet need of treating patients, with lesser hospitalization and a better prognosis. This is fueling the growth of innovations in the structural heart devices market. With the market poised to grow at a CAGR of 7.5% over the forecast period, the global structural heart devices market offers lucrative opportunities to emerging market players who are trying to gain a foothold in an industry that has lush benefits.

Tissue Engineered Heart Valves (TEHV), or biological valves, offer a new and advanced genre of treatment for patients who are in need of complete or partial valve replacement. Heart valves that are tissue engineered are a novel example of a live heart valve that consists of the host’s own tissues and cells. The biologic/tissue valves was the largest sector and accounted for ~55% of the market share in the year 2018. This is likely to reach a valuation of US$ 8 Bn by the end of the year 2027. The large-scale availability of transcatheter tissue valves and their adoption will fuel the growth of the structural heart devices market.

Xeltis is a clinical-stage medical device company that champions restorative solutions in patients needing cardiovascular therapy. Its structural heart devices sector has pioneered a procedure called Endogenous Tissue Restoration (ETR). Through this procedure, the patient is naturally able to restore a damaged heart valve. The latest innovation has been to use a polymer-based technology to restore cardiac function using ETR. With time, these devices can be developed on a large scale, obviating the cumbersome manufacturing processes involved with traditional biologic devices. Similarly, LivaNova’s ‘Perceval’ is the only suture-less, aortic tissue valve that is minimally-invasive, and is designed to be highly versatile in complex cardiomyopathy and acute cases of valvular stenosis. As these new devices are made available globally, the structural devices market will see new innovations and will gain momentum over the forecast period.

structural heart devices market infographic

To know the segments analyzed in the TMR report, ask for a brochure here.

Transcatheter Aortic Valve Replacement (TAVR) to Revolutionize Structural Heart Devices Market

Since structural heart diseases pertain to abnormalities in the heart’s anatomy, and these can lead to serious complications such as stroke, cardiac arrest, and heart failure. Traditionally, the only way to treat structural heart diseases was through an open heart surgery. In Aug 2019, the Food and Drug Administration (FDA) approved transcatheter aortic valve replacement (TAVR) as a suitable replacement technology for patients suffering from severe aortic stenosis. This procedure is highly recommended for patients who are younger and lead more active lifestyles.

Experts opine that, the recent FDA approval was in the offing, due to the procedure’s stupendous success in clinical trials. Its approval in low-risk patients paves the way for its proliferation over the next two years, as it will replace surgical valve replacement in a big way. The replacement procedures sector has been gaining significant momentum, and captured ~77% of the market share in the year 2018. The popularity and user-friendliness of TAVR procedures is likely to fuel the growth of the structural devices market over the next decade.

To know more about TMRs unique offerings for Structural Heart Devices Market, request a sample here

Winning Imperatives: R&D and Innovation to Fuel Structural Heart Devices Market

North America held a prominent share of the market in the year 2018. The structural devices market in North America is fueled by innovative procedures, research & development, and new product launches. For this reason, North America accounted for 42% of the global market in the year 2018.

Interventional catheter technologies are the new technologies and innovations that are shaping the structural heart devices market, of not only North America, but also the global market space. Hybrid procedures, healthcare reforms, and collaborations amongst surgeons, interventionists, and cardiologists will drive the growth of the structural heart devices landscape.

  • The evolution of hybrid procedures that include a mix of surgical and interventional procedures will give rise to the catheter lab or the hybrid operating room. These will be built to facilitate both the procedures by using a mix of modern equipment, sterility, high quality imaging systems, and ventilation. With multi-disciplinary capability, this will be a time-saving and cost-effective strategy, lowering healthcare costs and boosting the growth of the structural heart devices market.
  • Advancements in Computed Tomography (CT) scans will have an impact on catheter technologies in the structural heart devices market. Non-Invasive readings will be available to cardiologists and surgeons, which will help them map out the entire coronary tree in one CT scan. It will also enable the implantation of virtual stents and a visual depiction of how it will impact flow. This tool will reduce time and procedural costs, and will act as a fuel for the growth of the structural devices market.
  • 3D rotational angiography will see complete integration into other imaging solutions. This will create enhanced visualization of transcatheter procedures inside the body. A high level of 3D integration will be a very effective remedial step towards the treatment of chronic total occlusions (CTO). The structural heart devices market will gain traction with the incorporation of modern 3D rotational angiography.
structural heart devices market segmentation

Get a snapshot of the latest report on Structural Heart Devices Market with Custom Report here

New Product Launches and Acquisitions Define the Competitive Landscape

The competitive landscape of the structural heart devices market is highly consolidated with four major players, Edward Lifesciences Corporation, Abbott, Medtronic, and Boston Scientific Corporation account for ~92% of the total market share. Their growth strategy is centered around product innovations, patient care, and transformative catheter procedures.

Edward Lifesciences and Medtronic are the dominant leaders in the structural heart devices market landscape, and their rapid rise can be attributed to acquisitions, collaborations, product innovations, and sophisticated distribution channels that have allowed them to grow globally.

Edward Lifesciences has pioneered TAVR, which was approved by the FDA in Aug 2019. This innovative solution has further consolidated its position as a global leader in transformative healthcare, and has aided it in propelling ahead in the structural heart devices market. Its other product offerings are the SAPIEN 3 and SAPIEN XT. SAPIEN 3 is a trans-catheter heart valve that is artificial, and there are several accessories used to implant the valve without an open heart surgery. In Feb 2019, Edward Lifesciences entered into a merger agreement to acquire CAS Medical Systems, a medical technology company that deals with non-invasive monitoring of oxygen in the brain. This will strengthen Edward’s leadership in smart monitoring capabilities.

In Aug 2019, Medtronic announced the U.S FDA approval of its Evolut TAVR system for patients suffering from native stenosis. Evolut offers an excellent safety solution for low-risk patients with minimum hospital stay and excellent quality of life. In May 2019, Medtronic announced its decision to acquire Titan Spine, a privately-held titanium spine inter-body implant and surface technology company. With this merger, Medtronic will acquire Titan Spine’s entire range of innovative spinal titanium fusion devices. This will have a dramatic impact on both, the cardiac and spine market, and will fuel Medtronic’s growth in the structural heart devices market.

Micro Interventional Devices, Inc is an emerging player that designs and manufactures disruptive technologies for usage in structural heart repair procedures. Its products like the permavalve is a new-found catheter-based solution, and is said to drive the structural heart devices market.

In Mar 2019, Micro Interventional Devices Inc entered into a strategic alliance with OSCAR Inc. With this, both companies will be able to spearhead innovative solutions for structural heart diseases, and leverage their place in the market. Under this agreement, Micro Interventional Devices Inc acquires a global license to OSCAR’s patented catheter technology. This will give Micro Interventional Devices the technical prowess to ramp up production and enhance its revenue portfolio.

Analysts’ Perspective

A comprehensive view of the structural heart devices market has led our analysts to conclude that, the market is growing at a high CAGR, with North America holding a large chunk of the global demand for structural heart devices and their applications. The rising demand for structural heart device technology and its versatile applications in the treatment of cardiac diseases is spurring its demand. The impact of new innovations and product launches in the field of valve replacement will remain high on the structural heart devices market, globally. Strong financial position, acquisition strategies, and technological innovations of key market players will also give impetus to the structural heart devices market.

Technological breakthroughs such as TAVR and Hybrid therapy could provide timely relief as a cost-effective and time-saving strategy, thereby increasing profit margins for market players. Companies with research & development capabilities and technological prowess will gather momentum and profitability in the structural heart devices market. Leading players who are leveraging technology will continue to grow exponentially and have a vast market revenue share. However, stringent government regulations and high cost of minimally-invasive procedures could restrain the growth of the structural heart devices market.

  • According to Transparency Market Research’s latest report on the global structural heart devices market for the historical (2017–2018) and forecast period (2019–2027), rise in the number of transcatheter aortic valve replacement procedures across the globe, new product launches by key players, surge in diagnostic rates, and increase in awareness about structural heart diseases are the major drivers of the global structural heart devices market.
  • The global structural heart devices market is estimated to reach ~US$ 13 Bn by 2027, growing at a CAGR of 7.5% from 2019 to 2027.

Surge in Minimally-invasive Procedures: A Key Driver

  • Minimally-invasive procedures are non-surgical procedures that enable minimal incision, shorter hospital stay, lesser complications, and faster recovery.
  • There has been an increase in the use of structural heart devices that can be implanted through a minimally-invasive approach. Transcatheter aortic valve replacement (TAVR) is a procedure that allows insertion of heart valves without the need of an open heart surgery.
  • According to the National Institute for Cardiovascular Outcomes Research (NICOR) U.K. TAVI and Adult Cardiac Surgery databases, 13,295 TAVR procedures were performed in the U.K. from 2007 to 2016.
  • Hence, increase in the awareness about the advantages of minimally-invasive surgery has led to a surge in the adoption of these procedures in cardiology.

Increase in Awareness about Structural Heart Devices and Favorable Reimbursement Policies Drive Market

  • The global structural heart devices market is expanding at a rapid pace, owing to a surge in the awareness about structural heart diseases and favorable reimbursement policies for structural heart devices and procedures.
  • Awareness about structural heart diseases is increasing among the general population. A number of public and privately-held organizations are conducting awareness programs highlighting the risk factors, symptoms, diagnosis, and treatment options for valvular heart disease and other heart defects. These awareness programs are likely to contribute to the growth of the global structural heart devices market.
  • In 2017, Alliance for Aging Research (a non-profit organization) conducted the National Heart Valve Disease Awareness Day program. The primary objective of the program was to ensure that more people are aware about the risks and symptoms of heart valve diseases.
  • The European Heart Valve Disease Awareness Day program was conducted in September 2018 to improve the diagnosis, treatment, and management of heart valve disease in Europe.
  • Favorable reimbursement policies is another major factor anticipated to boost the growth of the global structural heart devices market during the forecast period. In March 2018, Abbott Laboratories announced that MitraClip was granted national reimbursement in Japan, which enables greater access for patients to this life-altering therapy.
  • However, stringent government approval processes and the high cost of minimally-invasive procedures are anticipated to hamper the growth of the global structural heart devices market.

Global Structural Heart Devices Market: Key Segments

  • In terms of procedure, the global structural heart devices market has been categorized into biological/tissue valves, mechanical heart valves, annuloplasty rings, occluders, and accessories. The biological/tissue valves segment has been bifurcated into transcatheter heart valves and surgical heart valves.
  • The biological/tissue valves segment accounted for a leading share of the global structural heart devices market in 2018. The segment is likely to dominate the global market during the forecast period.
  • Based on procedure, the global structural heart devices market has been segregated into replacement procedures and repair procedures. The replacement procedures segment is projected to account for a significant share of the global market during the forecast period.
  • In terms of indication, the global structural heart devices market has been classified into valve stenosis, valve regurgitation, cardiomyopathy, congenital heart defects, and others. In terms of market share, the valve stenosis segment is expected to dominate the global structural heart devices market during the forecast period.
  • The market size and forecast for each of these segments has been provided from 2017 to 2027. The CAGRs of respective segments are also provided for the forecast period from 2019 to 2027, considering 2018 as the base year.

Structural Heart Devices Market: Competitive Landscape

  • Prominent players in the global structural heart devices market have been profiled based on attributes, such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies.
  • The global structural heart devices market is consolidated, with the top three players accounting for ~80% share in 2018.
  • New product development for unmet needs such as mitral valve repair and replacement is a key strategy adopted by key players to be competitive in the global structural heart devices market. These players are also adopting inorganic growth strategies by acquiring small-scale manufacturers to expand market reach. These players strive to provide access to technologically-advanced devices for the treatment of structural heart diseases.
  • Major companies profiled in the global structural heart devices market report are
    • Medtronic
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Edwards Lifesciences Corporation
    • LivaNova plc
    • Lepu Medical
    • Micro Interventional Devices, Inc.
    • Lifetech Scientific
    • NeovasCryoLife, Inc.

Structural Heart Devices Market: Key Developments

  • In January 2019, Abbott acquired Cephea Valve Technologies, Inc., which strengthened Abbott’s position in the global structural heart devices market.
  • In March 2019, Abbott received the FDA approval for its MitraClip for the treatment of heart failure patients and mitral regurgitation.
  • In December 2018, Boston Scientific Corporation acquired transcatheter mitral valve repair system developer - Millipede, Inc.
  • In July 2017, Medtronic received CE mark for its CoreValve Evolut PRO valve for aortic stenosis. This enabled the company to enhance its customer reach and strengthen its product platform in the structural heart devices market in Europe.

In the global structural heart devices market report, we have discussed individual strategies, followed by company profiles of the manufacturers of structural heart devices. The competitive landscape section is included in the report to provide readers with a dashboard view and a company market share analysis of the key players operating in the global structural heart devices market.

Structural Heart Devices Market – Segmentation

In order to understand the finer details of the market, the report segments the structural heart devices market on the basis of product, procedure, indication, and region. This allows market stakeholders to assess incremental opportunities in this market landscape.

Product

Biological/Tissue Valves

  • Transcatheter Heart Valves
  • Surgical Heart Valves

Mechanical Heart Valves

Annuloplasty Rings

Occluders

Accessories

Procedure

Replacement Procedures

Repair Procedures

Indication

Valve Stenosis

Valve Regurgitation

Cardiomyopathy

Congenital Heart Defects

Others

Region

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Frequently Asked Questions

What is the total market worth of structural heart devices market?

Structural heart devices market is estimated to reach ~US$ 13 Bn by 2027

What is the anticipated CAGR of the structural heart devices market in the forecast period?

Structural heart devices market to Expand at a CAGR of 7.5% from 2019 to 2027

What are the key driving factors for the growth of the structural heart devices market?

Structural heart devices market is driven by surge in the awareness about structural heart diseases and favorable reimbursement policies

Which is the rising prominent segment in the structural heart devices market?

The biological/tissue valves segment accounted for a leading share of the global structural heart devices market and to dominate the global market during the forecast period

Who are the key players in the structural heart devices market?

Key players in the global structural heart devices market are Medtronic, Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova plc

    1. Preface
        1.1. Market Definition and Scope
        1.2. Market Segmentation
        1.3. Key Research Objectives
        1.4. Research Highlights
    2. Assumptions and Research Methodology
    3. Executive Summary: Global Structural Heart Devices Market
    4. Market Overview

        4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
        4.2. Overview
        4.3. Market Dynamics
            4.3.1. Drivers
                4.3.1.1. Surge in awareness about structural heart diseases
                4.3.1.2. Rise in prevalence of structural heart diseases
                4.3.1.3. Increase in demand for minimally invasive procedures
                4.3.1.4. Technological advancements in structural heart devices
                4.3.1.5. Favorable reimbursement policies
                4.3.1.6. Longer life expectancy along with increase in geriatric population
            4.3.2. Restraints
                4.3.2.1. Stringent government approval process
                4.3.2.2. High cost of minimally invasive procedures
            4.3.3. Opportunities
                4.3.3.1. Lucrative opportunities in emerging markets
                4.3.3.2. Increase in demand for heart valve repair procedures
        4.4. Global Structural Heart Devices Market Analysis and Forecast, 2019–2027
    5. Market Outlook
        5.1. Product Mapping
        5.2. Trials Mapping
        5.3. Price Comparison Analysis
        5.4. Technological Advancements
        5.5. Key Industry Events
    6. Global Structural Heart Devices Market Analysis and Forecast, by Product 
        6.1. Introduction & Definition
        6.2. Key Findings / Developments
        6.3. Market Value Forecast, by Product, 2019–2027
            6.3.1. Biological/Tissue Valves
                6.3.1.1. Transcatheter Heart Valves
                6.3.1.2. Surgical Heart Valve 
            6.3.2. Mechanical Heart Valves
            6.3.3. Annuloplasty Rings
            6.3.4. Occluders
            6.3.5. Accessories
        6.4. Market Attractiveness, by Product 
    7. Global Structural Heart Devices Market Analysis and Forecast, by Procedure 
        7.1. Introduction & Definition
        7.2. Key Findings / Developments
        7.3. Market Value Forecast, by Procedure, 2019–2027
            7.3.1. Replacement Procedure
            7.3.2. Repair Procedure 
        7.4. Market Attractiveness, by Procedure 
    8. Global Structural Heart Devices Market Analysis and Forecasts, by Indication 
        8.1. Introduction & Definition
        8.2. Key Findings / Developments
        8.3. Market Value Forecast, by Indication, 2019–2027
            8.3.1. Valve Stenosis
            8.3.2. Valve Regurgitation
            8.3.3. Cardiomyopathy
            8.3.4. Congenital Heart Defects
            8.3.5. Others
        8.4. Market Attractiveness, by Indication 
    9. Global Structural Heart Devices Market Analysis and Forecast, by Region
        9.1. Key Findings
        9.2. Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
        9.3. Market Attractiveness, by Region
    10. North America Structural Heart Devices Market Analysis and Forecast
        10.1. Introduction
            10.1.1. Key Findings
        10.2. Market Value Forecast, by Product, 2019–2027
            10.2.1. Biological/Tissue Valves
                10.2.1.1. Transcatheter Heart Valves
                10.2.1.2. Surgical Heart Valve 
            10.2.2. Mechanical Heart Valves
            10.2.3. Annuloplasty Rings
            10.2.4. Occluders
            10.2.5. Accessories
        10.3. Market Value Forecast, by Procedure, 2019–2027
            10.3.1. Replacement Procedure
            10.3.2. Repair Procedure 
        10.4. Market Value Forecast, by Indication, 2019–2027
            10.4.1. Valve Stenosis
            10.4.2. Valve Regurgitation
            10.4.3. Cardiomyopathy
            10.4.4. Congenital Heart Defects
            10.4.5. Others
        10.5. Market Value Forecast, by Country, 2019–2027
            10.5.1. U.S.
            10.5.2. Canada
        10.6. Market Attractiveness Analysis 
            10.6.1. By Product 
            10.6.2. By Procedure 
            10.6.3. By Indication 
            10.6.4. By Country
    11. Europe Structural Heart Devices Market Analysis and Forecast
        11.1. Introduction
            11.1.1. Key Findings
        11.2. Market Value Forecast, by Product, 2019–2027
            11.2.1. Biological/Tissue Valves
                11.2.1.1. Transcatheter Heart Valves
                11.2.1.2. Surgical Heart Valve 
            11.2.2. Mechanical Heart Valves
            11.2.3. Annuloplasty Rings
            11.2.4. Occluders
            11.2.5. Accessories
        11.3. Market Value Forecast, by Procedure, 2019–2027
            11.3.1. Replacement Procedure
            11.3.2. Repair Procedure 
        11.4. Market Value Forecast, by Indication, 2019–2027
            11.4.1. Valve Stenosis
            11.4.2. Valve Regurgitation
            11.4.3. Cardiomyopathy
            11.4.4. Congenital Heart Defects
            11.4.5. Others
        11.5. Market Value Forecast, by Country/Sub-region, 2019–2027
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
        11.6. Market Attractiveness Analysis 
            11.6.1. By Product 
            11.6.2. By Procedure 
            11.6.3. By Indication 
            11.6.4. By Country/Sub-region
    12. Asia Pacific Structural Heart Devices Market Analysis and Forecast
        12.1. Introduction
            12.1.1. Key Findings
        12.2. Market Value Forecast, by Product, 2019–2027
            12.2.1. Biological/ Tissue Valves
                12.2.1.1. Transcatheter Heart Valves
                12.2.1.2. Surgical Heart Valve 
            12.2.2. Mechanical Heart Valves
            12.2.3. Annuloplasty Rings
            12.2.4. Occluders
            12.2.5. Accessories
        12.3. Market Value Forecast, by Procedure, 2019–2027
            12.3.1. Replacement Procedure
            12.3.2. Repair Procedure 
        12.4. Market Value Forecast, by Indication, 2019–2027
            12.4.1. Valve Stenosis
            12.4.2. Valve Regurgitation
            12.4.3. Cardiomyopathy
            12.4.4. Congenital Heart Defects
            12.4.5. Others
        12.5. Market Value Forecast, by Country/Sub-region, 2019–2027
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
        12.6. Market Attractiveness Analysis 
            12.6.1. By Product 
            12.6.2. By Procedure 
            12.6.3. By Indication 
            12.6.4. By Country/Sub-region
    13. Latin America Structural Heart Devices Market Analysis and Forecast
        13.1. Introduction
            13.1.1. Key Findings
        13.2. Market Value Forecast, by Product, 2019–2027
            13.2.1. Biological/ Tissue Valves
                13.2.1.1. Transcatheter Heart Valves
                13.2.1.2. Surgical Heart Valve 
            13.2.2. Mechanical Heart Valves
            13.2.3. Annuloplasty Rings
            13.2.4. Occluders
            13.2.5. Accessories
        13.3. Market Value Forecast, by Procedure, 2019–2027
            13.3.1. Replacement Procedure
            13.3.2. Repair Procedure 
        13.4. Market Value Forecast, by Indication, 2019–2027
            13.4.1. Valve Stenosis
            13.4.2. Valve Regurgitation
            13.4.3. Cardiomyopathy
            13.4.4. Congenital Heart Defects
            13.4.5. Others
        13.5. Market Value Forecast, by Country/Sub-region, 2019–2027
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
        13.6. Market Attractiveness Analysis 
            13.6.1. By Product 
            13.6.2. By Procedure 
            13.6.3. By Indication 
            13.6.4. By Country/Sub-region
    14. Middle East & Africa Structural Heart Devices Market Analysis and Forecast
        14.1. Introduction
            14.1.1. Key Findings
        14.2. Market Value Forecast, by Product, 2019–2027
            14.2.1. Biological/ Tissue Valves
                14.2.1.1. Transcatheter Heart Valves
                14.2.1.2. Surgical Heart Valve 
            14.2.2. Mechanical Heart Valves
            14.2.3. Annuloplasty Rings
            14.2.4. Occluders
            14.2.5. Accessories
        14.3. Market Value Forecast, by Procedure, 2019–2027
            14.3.1. Replacement Procedure
            14.3.2. Repair Procedure 
        14.4. Market Value Forecast, by Indication, 2019–2027
            14.4.1. Valve Stenosis
            14.4.2. Valve Regurgitation
            14.4.3. Cardiomyopathy
            14.4.4. Congenital Heart Defects
            14.4.5. Others
        14.5. Market Value Forecast, by Country/Sub-region, 2019–2027
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
        14.6. Market Attractiveness Analysis 
            14.6.1. By Product 
            14.6.2. By Procedure 
            14.6.3. By Indication 
            14.6.4. By Country/Sub-region
    15. Competition Landscape
        15.1. Market Player - Competition Matrix (By Tier and Size of companies)
        15.2. Market Share Analysis, by Company, 2018
        15.3. Company Profiles
            15.3.1. Medtronic
                15.3.1.1. Company Overview
                15.3.1.2. Product Portfolio
                15.3.1.3. SWOT Analysis
                15.3.1.4. Financial Overview
                15.3.1.5. Strategic Overview
            15.3.2. CryoLife, Inc.
                15.3.2.1. Company Overview
                15.3.2.2. Product Portfolio
                15.3.2.3. SWOT Analysis
                15.3.2.4. Financial Overview
                15.3.2.5. Strategic Overview
            15.3.3. Abbott
                15.3.3.1. Company Overview
                15.3.3.2. Product Portfolio
                15.3.3.3. SWOT Analysis
                15.3.3.4. Financial Overview
                15.3.3.5. Strategic Overview
            15.3.4. Boston Scientific Corporation
                15.3.4.1. Company Overview
                15.3.4.2. Product Portfolio
                15.3.4.3. SWOT Analysis
                15.3.4.4. Financial Overview
                15.3.4.5. Strategic Overview
            15.3.5. Edwards Lifesciences Corporation
                15.3.5.1. Company Overview
                15.3.5.2. Product Portfolio
                15.3.5.3. SWOT Analysis
                15.3.5.4. Financial Overview
                15.3.5.5. Strategic Overview
            15.3.6. LivaNova PLC
                15.3.6.1. Company Overview
                15.3.6.2. Product Portfolio
                15.3.6.3. SWOT Analysis
                15.3.6.4. Financial Overview
                15.3.6.5. Strategic Overview
            15.3.7. Lepu Medical
                15.3.7.1. Company Overview
                15.3.7.2. Product Portfolio
                15.3.7.3. SWOT Analysis
                15.3.7.4. Strategic Overview
            15.3.8. Micro Interventional Devices, Inc. 
                15.3.8.1. Company Overview
                15.3.8.2. Product Portfolio
                15.3.8.3. SWOT Analysis
                15.3.8.4. Strategic Overview
            15.3.9. Lifetech Scientific
                15.3.9.1. Company Overview
                15.3.9.2. Product Portfolio
                15.3.9.3. SWOT Analysis
                15.3.9.4. Strategic Overview

    List of Tables

    Table 01: Structural Heart Device Product Mapping (1/6)
    Table 02: Structural Heart Device Product Mapping (2/6)
    Table 03: Structural Heart Device Product Mapping (3/6)
    Table 04: Structural Heart Device Product Mapping (4/6)
    Table 05: Structural Heart Device Product Mapping (5/6)
    Table 06: Structural Heart Device Product Mapping (6/6)
    Table 07: Ongoing Structural Heart Device Pipeline Analysis (1/7)
    Table 08: Ongoing Structural Heart Device Pipeline Analysis (2/7)
    Table 09: Ongoing Structural Heart Device Pipeline Analysis (3/7)
    Table 10: Ongoing Structural Heart Device Pipeline Analysis (4/7)
    Table 11: Ongoing Structural Heart Device Pipeline Analysis (5/7)
    Table 12: Ongoing Structural Heart Device Pipeline Analysis (6/7)
    Table 13: Ongoing Structural Heart Device Pipeline Analysis (7/7)
    Table 14: Average Heart Valve Pricing (US$), 2017–2018
    Table 15: Average Heart Valve Pricing (US$), 2017–2018
    Table 16: Average Heart Valve Pricing (US$), 2017
    Table 17: Global Structural Heart Devices Market, Product Launch and Regulatory Approvals, 2018–2019
    Table 18: Global Structural Heart Devices Market, Product Launch and Regulatory Approvals, 2017–2018
    Table 19: Global Structural Heart Devices Market, Product Launch and Regulatory Approvals, 2016–2017
    Table 20: Global Structural Heart Devices Market, Acquisitions, 2016–2019
    Table 21: Global Structural Heart Devices Market, Partnerships, Collaborations and Alliances, 2017–2019
    Table 22: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Product, 2017–2027
    Table 23: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
    Table 24: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Procedure, 2017–2027
    Table 25: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Indication, 2017–2027
    Table 26: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Region, 2017–2027
    Table 27: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
    Table 28: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
    Table 29: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
    Table 30: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
    Table 31: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Country, 2017–2027
    Table 32: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
    Table 33: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
    Table 34: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
    Table 35: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
    Table 36: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 37: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
    Table 38: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
    Table 39: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
    Table 40: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
    Table 41: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 42: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
    Table 43: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
    Table 44: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
    Table 45: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
    Table 46: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 47: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
    Table 48: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
    Table 49: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
    Table 50: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
    Table 51: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figures

    Figure 01: Global Structural Heart Devices Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
    Figure 02: Global Structural Heart Devices Market Value (US$ Mn), by Product, 2018
    Figure 03: Global Structural Heart Devices Market Top Two Trends, by Procedure and Indication, 2018
    Figure 04: Global Structural Heart Devices Market Overview
    Figure 05: Global Structural Heart Devices Market Value Share, by Product, 2018
    Figure 06: Global Structural Heart Devices Market Value Share, by Procedure, 2018
    Figure 07: Global Structural Heart Devices Market Value Share, by Indication, 2018
    Figure 08: Global Structural Heart Devices Market Value Share, by Region, 2018
    Figure 09: Global Structural Heart Devices Market Value (US$ Mn) Forecast, 2017–2027
    Figure 10: Key Market Developments 
    Figure 11: Global Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
    Figure 12: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Biological/Tissue Valves, 2017–2027
    Figure 13: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, Mechanical Heart Valves, 2017–2027
    Figure 14: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Annuloplasty Rings, 2017–2027
    Figure 15: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, Occluders, 2017–2027
    Figure 16: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Accessories, 2017–2027
    Figure 17: Global Structural Heart Devices Market Attractiveness Analysis, by Product, 2018–2026
    Figure 18: Global Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
    Figure 19: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Replacement Procedures, 2017–2027
    Figure 20: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Repair Procedures, 2017–2027
    Figure 21: Global Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2018–2027
    Figure 22: Global Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
    Figure 23: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Valve Stenosis, 2017–2027
    Figure 24: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Valve Regurgitation, 2017–2027
    Figure 25: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Cardiomyopathy, 2017–2027
    Figure 26: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Congenital Heart Defects, 2017–2027
    Figure 27: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
    Figure 28: Global Structural Heart Devices Market Attractiveness Analysis, by Indication, 2018–2027
    Figure 29: Global Structural Heart Devices Market Value Share Analysis, by Region, 2018 and 2027
    Figure 30: Global Structural Heart Devices Market Attractiveness Analysis, by Region, 2018–2026
    Figure 31: North America Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 32: North America Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
    Figure 33: North America Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
    Figure 34: North America Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
    Figure 35: North America Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
    Figure 36: North America Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
    Figure 37: North America Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019–2027
    Figure 38: North America Structural Heart Devices Market Value Share Analysis, by Country, 2018 and 2027
    Figure 39: North America Structural Heart Devices Market Attractiveness Analysis, by Country, 2019–2027
    Figure 40: Europe Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 41: Europe Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
    Figure 42: Europe Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
    Figure 43: Europe Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
    Figure 44: Europe Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
    Figure 45: Europe Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
    Figure 46: Europe Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019–2027
    Figure 47: Europe Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 48: Europe Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 49: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 50: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
    Figure 51: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
    Figure 52: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
    Figure 53: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
    Figure 54: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
    Figure 55: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019 -2027
    Figure 56: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 57: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 58: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 59: Latin America Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
    Figure 60: Latin America Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
    Figure 61: Latin America Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
    Figure 62: Latin America Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
    Figure 63: Latin America Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
    Figure 64: Latin America Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019 -2027
    Figure 65: Latin America Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 66: Latin America Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 67: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 68: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
    Figure 69: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
    Figure 70: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
    Figure 71: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
    Figure 72: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
    Figure 73: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019–2027
    Figure 74: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 75: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 76: Global Structural Heart Devices Market Share, by Company, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved